>>it does seem Tysabri has grown on you a bit with the time since re-launch and lack of safety signals to date. Is that a correct statement?
I was ready to put my wife on T when if was first on the market. In fact, we were likely only weeks from her starting T treatment. So I have felt for a long time that it was superior to the then existing alternatives. But with T pulled and my wife's neuro risk-averse, there was no chance to put my wife on T. We now have enough people on T - and for long enough that there should be plenty of lead time to protect my wife if the need arises. My wife's neuro (hand picked - top notch Wash U) is also ready. The third factor is that via plasma phoresis T can be quickly cleared if necessary.
I am not as familiar with Rituxan. But it offers two advantages, two infusions and 6 month response and what appears to me to be superior results off preliminary dosing. So we need to watch Rituxan.
My wife will soon start T so I will get some first hand impressions.
The risks of T against the certainty of MS progression offers a risk reward profile we can live with.
One last observation - it appears to me that neuro's who treat MS are becoming more active, treating earlier and more aggressively.
ij
Market Data 
Markets 
AI
